Literature DB >> 14763937

Skin test evaluation in nonimmediate allergic reactions to penicillins.

M-J Torres1, E Sánchez-Sabaté, J Alvarez, C Mayorga, J Fernández, A Padial, J-A Cornejo-García, T Bellón, M Blanca.   

Abstract

BACKGROUND: Nonimmediate reactions (NIR) to aminopenicillins (AP) are frequent. Although patch testing (PT) and intradermal testing (IT) are used for diagnosis, comparative results have never been adequately performed. We compared PT and IT in subjects with NIR to AP.
METHODS: Twenty-one subjects with NIR to AP and positive IT were re-evaluated. Skin tests were performed with amoxicillin (AX) and ampicillin (AM) at different concentrations in petrolatum, 50, 25, and 5% w/w, for PT and in saline, 20, 2, and 0.2 mg/ml for both PT and IT. Skin biopsies from the site of the positive response were studied with haematoxylin-eosin and immunohistochemistry.
RESULTS: In the re-evaluation, one case was IT and PT negative and was excluded; 20 were IT positive and 18 PT positive for both AX and AM. Decreasing concentrations of AP induced a reduction in positivity in both methods when diluted in saline, but not when mixed in petrolatum (PT only). With both PT and IT, immunohistochemical studies showed a perivascular mononuclear infiltrate with CD4 and CD8 memory cells expressing perforin and granzyme B.
CONCLUSIONS: Both tests appear valuable for the diagnosis of NIR to AP. However, IT diagnosed more patients than PT. The vehicle (saline or petrolatum) had no influence on the response, although in the former the concentration was critical. The immunohistochemical analysis showed skin infiltrates compatible with a T-cell drug reaction.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14763937     DOI: 10.1046/j.1398-9995.2003.00308.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  9 in total

Review 1.  General principles of investigating and managing drug allergy.

Authors:  Anthony Frew
Journal:  Br J Clin Pharmacol       Date:  2011-05       Impact factor: 4.335

Review 2.  Recent advances in the understanding of severe cutaneous adverse reactions.

Authors:  N R Adler; A K Aung; E N Ergen; J Trubiano; M S Y Goh; E J Phillips
Journal:  Br J Dermatol       Date:  2017-09-29       Impact factor: 9.302

Review 3.  Old dog begging for new tricks: current practices and future directions in the diagnosis of delayed antimicrobial hypersensitivity.

Authors:  Katherine C Konvinse; Elizabeth J Phillips; Katie D White; Jason A Trubiano
Journal:  Curr Opin Infect Dis       Date:  2016-12       Impact factor: 4.915

4.  Delabeling Delayed Drug Hypersensitivity: How Far Can You Safely Go?

Authors:  Rannakoe J Lehloenya; Jonny G Peter; Ana Copascu; Jason A Trubiano; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2020-10

Review 5.  Update on beta-lactam allergy diagnosis.

Authors:  Pascal Demoly; Antonino Romano
Journal:  Curr Allergy Asthma Rep       Date:  2005-01       Impact factor: 4.919

Review 6.  Non-immediate Cutaneous Reactions to Beta-Lactams: Approach to Diagnosis.

Authors:  Antonino Romano; Rocco Luigi Valluzzi; Cristiano Caruso; Michela Maggioletti; Francesco Gaeta
Journal:  Curr Allergy Asthma Rep       Date:  2017-04       Impact factor: 4.919

Review 7.  An Updated Review of the Diagnostic Methods in Delayed Drug Hypersensitivity.

Authors:  Ana Copaescu; Andrew Gibson; Yueran Li; Jason A Trubiano; Elizabeth J Phillips
Journal:  Front Pharmacol       Date:  2021-01-12       Impact factor: 5.810

8.  Piperacillin-Tazobactam Allergies: An Exception to Usual Penicillin Allergy.

Authors:  Jane Cy Wong; Elaine Yl Au; Heather Hf Yeung; Chak Sing Lau; Philip Hei Li
Journal:  Allergy Asthma Immunol Res       Date:  2021-03       Impact factor: 5.764

9.  COVID-19 mRNA Vaccine-induced Pneumonitis.

Authors:  Shinichi Matsuzaki; Hiroyuki Kamiya; Ichiro Inoshima; Yasutaka Hirasawa; Osamu Tago; Masashi Arai
Journal:  Intern Med       Date:  2021-10-26       Impact factor: 1.271

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.